3 most recent filings and news items mentioning CGEM. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/CGEM/news?limit=20"
Pull CGEM filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayCullinan Therapeutics reported encouraging Phase 1 clinical data for its CD19 and BCMA T cell engager programs targeting autoimmune diseases, with CLN-978 showing remissions in SLE and RA patients. The data supports advancement into additional indications and represents a potenti
View filing at SEC.gov →Cullinan Therapeutics announced initial clinical data for CLN-978, a CD19xCD3 T cell engager, demonstrating remissions in lupus and rheumatoid arthritis patients with a favorable safety profile. The positive Phase 1 results support advancement of the drug through clinical develop
View filing at SEC.gov →Cullinan Therapeutics announced initial clinical data from two Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, showing favorable safety profile and robust B cell depletion with early signals of clinical activity in treatment-refractory rheumatoid arthritis and systemic lup
View filing at SEC.gov →